Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra.

Although PEGylation of biologics is currently the gold standard for half-life extension, the technology has a number of limitations, most importantly the non-biodegradability of PEG and the extremely high viscosity at high concentrations. HESylation is a promising alternative based on coupling to the biodegradable polymer hydroxyethyl starch (HES). In this study, we are comparing HESylation with PEGylation regarding the effect on the protein's physicochemical properties, as well as on formulation at high concentrations, where protein stability and viscosity can be compromised. For this purpose, the model protein anakinra is coupled to HES or PEG by reductive amination. Results show that coupling of HES or PEG had practically no effect on the protein's secondary structure, and that it reduced protein affinity by one order of magnitude, with HESylated anakinra more affine than the PEGylated protein. The viscosity of HESylated anakinra at protein concentrations up to 75 mg/mL was approximately 40% lower than that of PEG-anakinra. Both conjugates increased the apparent melting temperature of anakinra in concentrated solutions. Finally, HESylated anakinra was superior to PEG-anakinra regarding monomer recovery after 8 weeks of storage at 40°C. These results show that HESylating anakinra offers formulation advantages compared with PEGylation, especially for concentrated protein solutions.

[1]  R. Rudolph,et al.  Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.

[2]  A. Pappenberger,et al.  Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. , 2011, Journal of pharmaceutical sciences.

[3]  P. Pranay,et al.  Characterization of protein rheology and delivery forces for combination products. , 2012, Journal of pharmaceutical sciences.

[4]  A. Skerra Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.

[5]  B. Chang,et al.  Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. , 2004, Journal of Pharmacy and Science.

[6]  H. Senn,et al.  Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.

[7]  M. Scholle,et al.  Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.

[8]  Y. Levy,et al.  Folding of glycoproteins: toward understanding the biophysics of the glycosylation code. , 2009, Current opinion in structural biology.

[9]  G. McKinley,et al.  Microfluidic rheometry , 2008 .

[10]  Sandeep Yadav,et al.  Specific interactions in high concentration antibody solutions resulting in high viscosity. , 2010, Journal of pharmaceutical sciences.

[11]  M. Emgenbroich,et al.  Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. , 2012, Cytokine.

[12]  W. Berthold,et al.  Polyethylene glycol-conjugated pharmaceutical proteins , 1998 .

[13]  G. Hause,et al.  Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. , 2007, Biomacromolecules.

[14]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[15]  Haeshin Lee,et al.  N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor , 2003, Pharmaceutical Research.

[16]  W. Kulicke,et al.  Measurements of the refractive index increment on hydroxyethyl starch as a basis for absolute molecular weight determinations , 1991 .

[17]  Guifeng Zhang,et al.  Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. , 2007, Bioorganic & medicinal chemistry.

[18]  Z. Su,et al.  PEGylation of rhIL-1RA increased its solution stability at room temperature , 2009 .

[19]  I. Theobald,et al.  Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. , 2007, Protein engineering, design & selection : PEDS.

[20]  D. Rudmann,et al.  High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.

[21]  F. Veronese,et al.  PEGylated Protein Drugs: Basic Science and Clinical Applications , 2009 .

[22]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[23]  B. Luxon,et al.  Pegylated interferons for the treatment of chronic hepatitis C infection. , 2002, Clinical therapeutics.

[24]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  J. Bi,et al.  Facile purification of mono-PEGylated interleukin-1 receptor antagonist and its characterization with multi-angle laser light scattering , 2007 .

[26]  Wei Liu,et al.  High‐throughput measurement, correlation analysis, and machine‐learning predictions for pH and thermal stabilities of Pfizer‐generated antibodies , 2011, Protein science : a publication of the Protein Society.

[27]  J. Freed,et al.  Characterization of a low molecular weight isoform of IL-1 receptor antagonist. , 1998, Journal of immunology.

[28]  H. Bunjes,et al.  Comparison of different protein concentration techniques within preformulation development. , 2011, International journal of pharmaceutics.

[29]  D. Brems,et al.  Characterization and Stability of N-terminally PEGylated rhG-CSF , 1996, Pharmaceutical Research.

[30]  Gerhard Winter,et al.  Influence of hydroxypropyl-Beta-cyclodextrin on the stability of dilute and highly concentrated immunoglobulin g formulations. , 2013, Journal of pharmaceutical sciences.

[31]  D. Wuttke,et al.  High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization. , 2008, Journal of pharmaceutical sciences.

[32]  R. P. Garay,et al.  Immunogenicity of Polyethylene Glycol (PEG) , 2011 .

[33]  G. Winter,et al.  Challenges for PEGylated Proteins and Alternative Half-Life Extension Technologies Based on Biodegradable Polymers , 2013 .

[34]  P. Kingshott,et al.  Characterisation and physical stability of PEGylated glucagon. , 2007, International journal of pharmaceutics.

[35]  A. Plückthun,et al.  Protein PEGylation Decreases Observed Target Association Rates via a Dual Blocking Mechanisms⃞ , 2005, Molecular Pharmacology.

[36]  Zai-Qing Wen,et al.  Conformation and side chains environments of recombinant human interleukin-1 receptor antagonist (rh-IL-1ra) probed by raman, raman optical activity, and UV-resonance Raman spectroscopy. , 2008, Journal of pharmaceutical sciences.

[37]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[38]  J. Engberts,et al.  Aqueous solutions that model the cytosol: studies on polarity, chemical reactivity and enzyme kinetics. , 2004, Organic & biomolecular chemistry.

[39]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[40]  L. Setton,et al.  Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. , 2007, Arthritis and rheumatism.

[41]  Wolfgang Friess,et al.  High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants. , 2013, Journal of pharmaceutical sciences.

[42]  Jan Jezek,et al.  Viscosity of concentrated therapeutic protein compositions. , 2011, Advanced drug delivery reviews.

[43]  T. Arakawa,et al.  Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. , 1996, Biophysical journal.

[44]  T. Palm,et al.  The effect of PEGylation on the stability of small therapeutic proteins , 2011, Pharmaceutical development and technology.

[45]  Deirdre Murphy Piedmonte,et al.  Formulation of Neulasta (pegfilgrastim). , 2008, Advanced drug delivery reviews.

[46]  B. Manjula,et al.  Non-hypertensive tetraPEGylated canine haemoglobin: correlation between PEGylation, O2 affinity and tissue oxygenation. , 2007, The Biochemical journal.

[47]  Theodore W Randolph,et al.  High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. , 2008, Journal of pharmaceutical sciences.

[48]  R. Kontermann Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[49]  Ken A. Dill,et al.  Theory for the aggregation of proteins and copolymers , 1992 .

[50]  D. Brems,et al.  Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study , 2006, Protein science : a publication of the Protein Society.

[51]  B. Stockman,et al.  Solution structure of human interleukin‐1 receptor antagonist protein , 1994, FEBS Letters.

[52]  T. Hey,et al.  Half‐Life Extension through HESylation® , 2012 .

[53]  C. Klofutar,et al.  Viscosity of aqueous solutions of poly(ethylene glycol)s at 298.15 K , 1999 .

[54]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[55]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[56]  Roman Mathaes,et al.  Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[57]  Bruce A Kerwin,et al.  Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. , 2005, Biochemistry.

[58]  G. Gregoriadis,et al.  Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics , 2000, Cellular and Molecular Life Sciences CMLS.

[59]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[60]  A. Malavalli,et al.  Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. , 2007, Translational research : the journal of laboratory and clinical medicine.

[61]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[62]  D. Kalonia,et al.  Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations , 2006, AAPS PharmSciTech.

[63]  H. Mach,et al.  High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.

[64]  J. Kressler,et al.  Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. , 2009, Journal of pharmaceutical sciences.

[65]  Willem P C Stemmer,et al.  A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.

[66]  P. Taupin,et al.  PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals , 2009 .

[67]  A. Minton,et al.  Influence of macromolecular crowding upon the stability and state of association of proteins: predictions and observations. , 2005, Journal of pharmaceutical sciences.

[68]  Robert W. Payne,et al.  Product development issues for PEGylated proteins , 2011, Pharmaceutical development and technology.

[69]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[70]  Nitin Rathore,et al.  Variability in Syringe Components and its Impact on Functionality of Delivery Systems , 2011, PDA Journal of Pharmaceutical Science and Technology.

[71]  J. Kressler,et al.  Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES). , 2011, International journal of pharmaceutics.

[72]  W. Friess,et al.  FTIR and nDSC as Analytical Tools for High-Concentration Protein Formulations , 2006, Pharmaceutical Research.

[73]  T. Neff,et al.  Pharmacokinetics of Hydroxyethyl Starch , 2005, Clinical pharmacokinetics.

[74]  A. Klibanov,et al.  Hydrophobic salts markedly diminish viscosity of concentrated protein solutions , 2011, Biotechnology and bioengineering.

[75]  Interleukin-1 Receptor Antagonist Protein : Solution Secondary Structure from NOE ' s and 1 H « and 13 C « Chemical Shifts , 2007 .

[76]  G. Maurer,et al.  Osmotic Virial Coefficients of Aqueous Poly(ethylene glycol) from Laser-Light Scattering and Isopiestic Measurements , 1995 .

[77]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[78]  M. Emgenbroich,et al.  AGEM400(HES), a Novel Erythropoietin Mimetic Peptide Conjugated to Hydroxyethyl Starch with Excellent In Vitro Efficacy , 2010 .

[79]  F. Veronese,et al.  Protein PEGylation, basic science and biological applications , 2009 .